Üçler KISA, İsmail Yaşar AVCI, Onur SAYGUN, Can Polat EYİGÜN, Alaaddin PAHSA

Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection

Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated. Materials and Methods: Seventeen individuals vaccinated previously were enrolled in the study. They had once developed a protective level of anti-HBs antibody after immunization and their anti-HBs titer had declined to an underprotective level. Twenty uninfected and unvaccinated healthy people were chosen as controls. Lymphoproliferative response to in-vitro stimulation with hepatitis B surface antigen (HBsAg) and anti-HBs response to vaccine were evaluated for immune response. Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg stimulation while none of the controls did (P < 0.05). In all subjects in the study group, anti-HBs response (>= 10 mIU/ml) was detected 1 to 7 days after the booster injection but in only 2 of the controls antibody response was detected 28 days after the first dose of HBV vaccine (P < 0.0001). Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.

Anahtar Kelimeler:

HBV vaccination, long-term protection, booster dose requirement, immunological memory

Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection

Keywords:

HBV vaccination, long-term protection, booster dose requirement, immunological memory,

PDF

___

Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45. 2.
Thiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature
Coursaget P, Leboulleux D, Soumare M. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. Lancet 1994; 21: 250-4.
Hadler SC, Coleman PJ, O’Malley P, Judson FN, Altman N. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. Viral Hepatitis and Liver Disease, (Eds) Hollinger FB, Lemon SM, Margolis HS, Williams and Wilkins, Baltimore, 1991, 766-768.
Hwang LY, Lee CY, Beasley RP. Five-year follow-up of HBV vaccination with plasma-derived vaccine in neonates: evaluation of immunogenicity and efficacy against perinatal transmission. Viral Hepatitis and Liver Disease, (Eds) Hollinger FB, Lemon SM, Margolis HS, Williams and Wilkins, Baltimore, 1991, 759-761.
West DJ, Calandra GB: Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019-25.
West DJ. Immunologic memory and hepatitis B immunization. Proceedings of the IX Triennial International Symposium on Viral Hepatitis and Liver Disease (Abs), (Eds) Rizzetto M, Purcell RH, Gerin JL, Verme G, Edizioni Minerva Medica pp: 673-674, 1997.
Eyigün CP, Yılmaz S, Gül C, Şengül A, Hacıbektaşoğlu A, Van Thiel DH. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults. Journal of Viral Hepatitis 1998; 5: 265-69.
European Consensus Group on Hepatitis B immunity: Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-5.
Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long- term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999; 29: 954-9.
Leroux G, Van Hecke E, Michielson W, Voet P, Hauser P, Petre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunisation with hepatitis B surfage antigen (HBsAg) vaccines. Vaccine 1994; 12: 812-8.
Nagaraju K, Naik SR, Naik S. Lack of in vitro lymphoproliferative response to hepatitis B surface antigen in healthy vaccine recipients. Indian J Med Res 1998; 108: 80-4.
Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. Journal of Medical Virology 1998; 24: 377-84.
Krugman S, Davidson M. Hepatitis B vaccine: prospects for duration of immunity. Yale J Biol Med 1987; 60: 333-8.
Milne A, Krugman S, Waldon J. Hepatitis B vaccination in children: five year booster study, NZ Med J 1992; 105: 336-8.
Milne A, Waldon J. Recombinant DNA Hepatitis B vaccination in teenagers: effect of a booster dose at 5.5 Years. J Infect Dis 1992; 166: 942.
Wang RX, Boland GJ, van Hattum J, de Gast GC. Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol. 2004; 10: 260-3.
Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. A 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol. 2004; 2: 941-5.
Linder N, Vishne TH, Levin E, Handsher R, Fink-Kremer I, Waldman D, et al. A hepatitis B vaccination: long-term follow-up of the immune response of preterm infants and comparison of two vaccination protocols. Infection. 2002; 30: 136-9.
Lee CY, Huang LM, Chang MH, Hsu CY, Wu SJ, Sung JL, et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991; 10: 299-303.
Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapelière P, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992; 11: 816-21.
Resti M, Azzari C, Rossi ME, Adami Lami C, Tucci F, Vierucci A. Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses. Vaccine 1991; 9: 15-8.
Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of hepatitis B virus infection. Implications of childhood vaccination and long-term protection. Pediatrics 1992; 90: 170- 3.